Serveur d'exploration Tocilizumab

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management

Identifieur interne : 003B78 ( Main/Exploration ); précédent : 003B77; suivant : 003B79

Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management

Auteurs : Ashima Makol ; Kerry Wright ; Shreyasee Amin

Source :

RBID : Pascal:12-0019632

Descripteurs français

English descriptors

Abstract

Pregnancy can pose a challenge to the physician caring for women with rheumatoid arthritis (RA). While many women with RA experience a spontaneous improvement in joint pain and inflammation during pregnancy, in others it remains active and they continue to need ongoing therapy. It is important to tailor the treatment regimen so that the disease is stabilized prior to conception and to use medications that are safe throughout pregnancy and lactation. The use of immunomodulating medications considered low risk during pregnancy allows for optimal outcomes. NSAIDs should be avoided in the third trimester. Corticosteroids may be used throughout pregnancy in the lowest effective dose. Antimalarial agents, sulfasalazine and azathioprine are safe options, but methotrexate and leflunomide are contraindicated as they are teratogenic and must, therefore, be withdrawn before a planned pregnancy. The risk for some of the newer biological therapies for RA is not necessarily their proven teratogenicity, but the absence of proven safety for the fetus. As such, it is recommended that abatacept, rituximab and tocilizumab be withheld prior to pregnancy; however, tumour necrosis factor inhibitors and anakinra may be continued until conception.


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management</title>
<author>
<name sortKey="Makol, Ashima" sort="Makol, Ashima" uniqKey="Makol A" first="Ashima" last="Makol">Ashima Makol</name>
<affiliation>
<wicri:noCountry>no AF</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Wright, Kerry" sort="Wright, Kerry" uniqKey="Wright K" first="Kerry" last="Wright">Kerry Wright</name>
<affiliation>
<wicri:noCountry>no AF</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Amin, Shreyasee" sort="Amin, Shreyasee" uniqKey="Amin S" first="Shreyasee" last="Amin">Shreyasee Amin</name>
<affiliation>
<wicri:noCountry>no AF</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">12-0019632</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 12-0019632 INIST</idno>
<idno type="RBID">Pascal:12-0019632</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000127</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000137</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000145</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000145</idno>
<idno type="wicri:doubleKey">0012-6667:2011:Makol A:rheumatoid:arthritis:and</idno>
<idno type="wicri:Area/Main/Merge">003C19</idno>
<idno type="wicri:Area/Main/Curation">003B78</idno>
<idno type="wicri:Area/Main/Exploration">003B78</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management</title>
<author>
<name sortKey="Makol, Ashima" sort="Makol, Ashima" uniqKey="Makol A" first="Ashima" last="Makol">Ashima Makol</name>
<affiliation>
<wicri:noCountry>no AF</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Wright, Kerry" sort="Wright, Kerry" uniqKey="Wright K" first="Kerry" last="Wright">Kerry Wright</name>
<affiliation>
<wicri:noCountry>no AF</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Amin, Shreyasee" sort="Amin, Shreyasee" uniqKey="Amin S" first="Shreyasee" last="Amin">Shreyasee Amin</name>
<affiliation>
<wicri:noCountry>no AF</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Drugs : (Basel)</title>
<title level="j" type="abbreviated">Drugs : (Basel)</title>
<idno type="ISSN">0012-6667</idno>
<imprint>
<date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Drugs : (Basel)</title>
<title level="j" type="abbreviated">Drugs : (Basel)</title>
<idno type="ISSN">0012-6667</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Abatacept</term>
<term>Anakinra</term>
<term>Antiinflammatory agent</term>
<term>Antimalarial</term>
<term>Antineoplastic agent</term>
<term>Antirheumatic agent</term>
<term>Azathioprine</term>
<term>Breast feeding</term>
<term>Chloroquine</term>
<term>Chronic</term>
<term>Corticosteroid</term>
<term>Drug</term>
<term>Female</term>
<term>Immunomodulator</term>
<term>Immunosuppressive agent</term>
<term>Leflunomide</term>
<term>Methotrexate</term>
<term>Non steroidal antiinflammatory agent</term>
<term>Parasiticide</term>
<term>Pharmacotherapy</term>
<term>Pregnancy</term>
<term>Review</term>
<term>Rheumatoid arthritis</term>
<term>Rituximab</term>
<term>Secondary effect</term>
<term>Sulfasalazine</term>
<term>Tocilizumab</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Polyarthrite rhumatoïde</term>
<term>Gestation</term>
<term>Femelle</term>
<term>Toxicité</term>
<term>Effet secondaire</term>
<term>Pharmacothérapie</term>
<term>Article synthèse</term>
<term>Médicament</term>
<term>Antiinflammatoire non stéroïde</term>
<term>Corticostéroïde</term>
<term>Chloroquine</term>
<term>Sulfasalazine</term>
<term>Azathioprine</term>
<term>Méthotrexate</term>
<term>Léflunomide</term>
<term>Anakinra</term>
<term>Abatacept</term>
<term>Rituximab</term>
<term>Tocilizumab</term>
<term>Allaitement</term>
<term>Chronique</term>
<term>Antipaludique</term>
<term>Antiparasitaire</term>
<term>Antirhumatismal</term>
<term>Antiinflammatoire</term>
<term>Immunodépresseur</term>
<term>Anticancéreux</term>
<term>Immunomodulateur</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Pregnancy can pose a challenge to the physician caring for women with rheumatoid arthritis (RA). While many women with RA experience a spontaneous improvement in joint pain and inflammation during pregnancy, in others it remains active and they continue to need ongoing therapy. It is important to tailor the treatment regimen so that the disease is stabilized prior to conception and to use medications that are safe throughout pregnancy and lactation. The use of immunomodulating medications considered low risk during pregnancy allows for optimal outcomes. NSAIDs should be avoided in the third trimester. Corticosteroids may be used throughout pregnancy in the lowest effective dose. Antimalarial agents, sulfasalazine and azathioprine are safe options, but methotrexate and leflunomide are contraindicated as they are teratogenic and must, therefore, be withdrawn before a planned pregnancy. The risk for some of the newer biological therapies for RA is not necessarily their proven teratogenicity, but the absence of proven safety for the fetus. As such, it is recommended that abatacept, rituximab and tocilizumab be withheld prior to pregnancy; however, tumour necrosis factor inhibitors and anakinra may be continued until conception.</div>
</front>
</TEI>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Amin, Shreyasee" sort="Amin, Shreyasee" uniqKey="Amin S" first="Shreyasee" last="Amin">Shreyasee Amin</name>
<name sortKey="Makol, Ashima" sort="Makol, Ashima" uniqKey="Makol A" first="Ashima" last="Makol">Ashima Makol</name>
<name sortKey="Wright, Kerry" sort="Wright, Kerry" uniqKey="Wright K" first="Kerry" last="Wright">Kerry Wright</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B78 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B78 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:12-0019632
   |texte=   Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021